Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes

Deletion of the long arm of chromosome 5, del(5q), is the most prevalent cytogenetic abnormality in patients with myelodysplastic syndromes (MDS). In isolation, it is traditionally associated with favorable prognosis compared with other subtypes of MDS. However, owing to the inherent heterogeneity o...

Descripción completa

Detalles Bibliográficos
Autores principales: Giagounidis, Aristoteles, Mufti, Ghulam J., Fenaux, Pierre, Germing, Ulrich, List, Alan, MacBeth, Kyle J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889654/
https://www.ncbi.nlm.nih.gov/pubmed/24018623
http://dx.doi.org/10.1007/s00277-013-1863-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889654/
https://www.ncbi.nlm.nih.gov/pubmed/24018623
http://dx.doi.org/10.1007/s00277-013-1863-5

Ejemplares similares